Navigation Links
Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/10/2011

SAN DIEGO, March 10, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced 2010 fourth quarter and full year financial results and accomplishments.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Optimer reported a net loss for the three months ended December 31, 2010 of $11.9 million, or $0.31 per common share, as compared to a net loss of $9.4 million, or $0.28 per common share, for the same period in 2009.  Optimer reported a net loss for the year ended December 31, 2010 of $47.3 million, or $1.25 per common share, as compared to a net loss of $42.1 million, or $1.30 per common share, for 2009. The increase of $5.2 million was due primarily to a $3.6 million increase in stock compensation expense, an increase in market research and pre-commercial launch efforts related to our fidaxomicin program, and increases in consulting, recruitment and compensation expenses. The increases were offset by a decrease in development and manufacturing set-up expenses reimbursable to Biocon, Inc. incurred in the prior year in connection with commercial manufacturing scale-up.  The 2010 results include a $5 million milestone payment to Par for the successful completion of the second fidaxomicin Phase 3 trial and a $1.5 million regulatory filing fee for fidaxomicin.  

As of December 31, 2010, Optimer held cash, cash equivalents and short-term investments of $49.4 million.  In February 2011, Optimer raised an additional $73.1 million of net proceeds in a public offering of common stock. In March 2011, Optimer also received a $69.2 million upfront cash payment from Astellas Pharma under the terms of the collaboration agreement announced in February 2011.  

"In 2010, we completed our second fidaxomicin Phase 3 clinical trial, su
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Pa. , July 28, 2014  Air Products ... uninterrupted supply of medical oxygen is vital to any ... technical innovations that not only improve the efficiency of ... Air Products will highlight these systems—including systems for ... reduce oxygen loss—from August 4-5 at the 51 ...
(Date:7/28/2014)... BIRMINGHAM, Ala. , July 28, 2014 /PRNewswire-USNewswire/ ... Arthur J. Tipton , Ph.D., President and CEO ... of the Controlled Release Society (CRS) for the ... Society,s annual meeting on July 12 in ... than 40 countries.  The Controlled ...
(Date:7/28/2014)... , July 28, 2014  A prospective ... Sweden has validated the performance ... platforms and has associated volumetrically assessed breast density ... Cancer Epidemiology, Biomarkers & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), ... a tool for widespread breast cancer risk assessment," ...
Breaking Medicine Technology:Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4
... BioCryst Says Study Confirms and Extends Evidence Seen ... /PRNewswire-FirstCall/ --,BioCryst Pharmaceuticals, Inc. today announced that investigators,at ... results evaluating peramivir treatment in an animal model,of ... virus (an avian,influenza strain that had caused fatal ...
... data show efficacy across the range of migraine ... many migraine,sufferers experience traditional symptoms such as nausea ... also involve,symptoms like neck pain or sinus pain ... data show that,significantly more patients using the investigational ...
Cached Medicine Technology:St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection 2St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection 3St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection 4St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection 5St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection 6Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 2Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 3Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 4Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 5
(Date:7/29/2014)... 2014 The global market for audiology ... 2020, growing at an estimated CAGR of 5.0% from ... Grand View Research, Inc. Introduction of technological advancements such ... geriatric population, along with increase in demand of cost-effective ... of this market. In addition, presence of untapped growth ...
(Date:7/29/2014)... 2014 On Friday, the United States ... week of October 12-18, 2014, as "National Case Management ... improving healthcare outcomes for patients. The resolution was introduced ... (R-AR), with support by the Case Management Society of ... case management professionals for their contributions to healthcare. , ...
(Date:7/29/2014)... “Our years of experience with insulation ... insulate their homes properly simply due to lack ... transfer and conduction,” Clean Crawls says in their ... an article explaining exactly how heat transfer ... , To contact Clean Crawls for their professional ...
(Date:7/29/2014)... July 29, 2014 “Approximately 18% of ... the most common chronic illnesses,” Western Washington Medical Group ... the need for those suffering from allergies to seek ... allergy-related health care each year in the United States,” ... mere way of life for themselves, rather than seeking ...
(Date:7/29/2014)... Award-winning inventor Michael Croix has launched an Indiegogo ... to absorb embarrassing odors in the office. PoofPad is a ... in a desk drawer. This compact packaging is designed for ... sit on the pad and poof away! , “We’ve all ... BAM, someone appears out of nowhere. It’s embarrassing and unpleasant ...
Breaking Medicine News(10 mins):Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 2Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 4Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 5Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 6Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:What’s The Point of Insulation? Clean Crawls Explains The Dangers of Heat Transfer in Recently Released Article 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 3Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 3
... uncovered mutations throughout the mitochondrial genome that are associated ... published by Cell Press on December 2 in the ... association of tRNA mutations with elevated levels of prostate-specific ... of prostate cancer. Prostate cancer is among the ...
... inaugural James W. Varnum National Quality Award was presented ... Medical Center (CCHMC), in a ceremony held on Wednesday, ... Hampshire. , Receiving the award were Project SEARCH ... Disability Services; and Dr. Linda Workman, Vice President of ...
... drug reduces the incidence of non-melanoma skin cancers ... a study published this week in the Journal ... inhibitor celecoxib (brand name Celebrex), which is currently approved ... pain in adults led to a 62 percent reduction ...
... official congress of the European Association of Echocardiography (EAE), ... 11 December 2010. The latest techniques in non-invasive diagnostic ... full programme of 200 scientific papers, poster sessions and ... European Society of Cardiology. Sophia Antipolis, 2 ...
... Dec. 2 (HealthDay News) -- You,re likely looking forward to spending ... you should take steps to ensure you and everyone else avoids ... Here are some tips: , Use air kisses instead ... hand sanitizer with you. , Don,t use your fingers when eating ...
... , WEDNESDAY, Dec. 1 (HealthDay News) -- Crohn,s disease ... contends. The study included nearly 600 Swiss adults ... causes severe pain and diarrhea. The study participants ... and 19 percent of them were found to have ...
Cached Medicine News:Health News:Genetic mutations associated with increased PSA and prostate cancer 2Health News:James W. Varnum National Quality Award presented to Project SEARCH 2Health News:James W. Varnum National Quality Award presented to Project SEARCH 3Health News:Widely used arthritis pill protects against skin cancer 2Health News:Widely used arthritis pill protects against skin cancer 3Health News:1 week to go until the EUROECHO 2010 Congress in Copenhagen 2Health News:Study Suggests Link Between Crohn's Disease and PTSD 2
MediNotes e is an EMR design which utilizes a "tab concept for navigation. MediNotes e can display multiple patients, encounter notes, workflow items, patient flow, messages, alerts, and more, all in...
... Accumedics Electronic Medical ... real-time HL7 EDI Interface ... demographics, and provides custom ... Record Software Interface is ...
... RecordsTFC System supports approaches to ... patient/resident record keeping functions using ... multiple facilities and cut across ... clinics, community clinics, physician, agency, ...
... was developed expressly to help you ... applying the right combination of EMR ... you can be confident your practice ... What's more, athenaClinicals seamlessly integrates ...
Medicine Products: